GlassScriptPhysician profile
Grant Daniel Thimesch
NPI 1770267197
$8,237.41
in general payments reported to CMS, 2019-2025
23 companies · $4,164 in 2025
The $4,164 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $955 · 2024: $3,119 · 2025: $4,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,958 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,958.43 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $934.05 | 2024-2025 | |
| Abbvie INC. | $774.59 | 2023-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $727.17 | 2023-2025 | Ilumya |
| Dermavant Sciences, INC. | $668.37 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $622.74 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $591.81 | 2024-2025 | Nemluvio |
| Ucb, INC. | $531.59 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $512.68 | 2024-2025 | |
| Leo Pharma INC. | $424.49 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $423.96 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $406.76 | 2023-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.19 | 2024-2025 | Spevigo |
| Incyte Corporation | $310.76 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $248.80 | 2023-2025 | Zoryve |
| Kerecis Limited | $139.45 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $122.84 | 2024 | Ovitex 2s |
| Organon LLC | $111.68 | 2025 | Vtama |
| Biofrontera INC. | $93.12 | 2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Pfizer INC. | $56.49 | 2025 | |
| Lilly USA, LLC | $40.02 | 2025 | Taltz, Ebglyss |
| Almirall LLC | $38.87 | 2024 | Klisyri |
| Botanix Sb INC | $19.99 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Thimesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.